Invesco
HCAT icon

Invesco’s Health Catalyst HCAT Stock Holding History

Invesco’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150K Sell
118,130
-461
-0.4% -$867 ﹤0.01% 3561
2025
Q4 		$283K Buy
118,591
+7,186
+6% +$19.7K ﹤0.01% 3404
2025
Q3 		$318K Buy
111,405
+5,037
+5% +$17.2K ﹤0.01% 3396
2025
Q2 		$401K Buy
106,368
+8,769
+9% +$34.5K ﹤0.01% 3262
2025
Q1 		$442K Buy
97,599
+17,725
+22% +$93.8K ﹤0.01% 3196
2024
Q4 		$565K Buy
79,874
+1,623
+2% +$12.9K ﹤0.01% 3186
2024
Q3 		$637K Sell
78,251
-698
-0.9% -$5.04K ﹤0.01% 3125
2024
Q2 		$504K Sell
78,949
-2,664
-3% -$17.1K ﹤0.01% 3264
2024
Q1 		$615K Buy
81,613
+15,022
+23% +$137K ﹤0.01% 3229
2023
Q4 		$617K Sell
66,591
-10,666
-14% -$87.2K ﹤0.01% 3115
2023
Q3 		$782K Buy
77,257
+11,936
+18% +$142K ﹤0.01% 2982
2023
Q2 		$817K Sell
65,321
-53,259
-45% -$634K ﹤0.01% 2982
2023
Q1 		$1.38M Buy
118,580
+23,180
+24% +$295K ﹤0.01% 2778
2022
Q4 		$1.01M Sell
95,400
-2,855
-3% -$27.6K ﹤0.01% 2928
2022
Q3 		$953K Sell
98,255
-746,028
-88% -$9.88M ﹤0.01% 2944
2022
Q2 		$12.2M Buy
844,283
+99,855
+13% +$1.7M ﹤0.01% 1703
2022
Q1 		$19.5M Buy
744,428
+60,652
+9% +$1.72M 0.01% 1534
2021
Q4 		$27.1M Buy
683,776
+48,984
+8% +$2.23M 0.01% 1363
2021
Q3 		$31.7M Buy
634,792
+549,923
+648% +$30M 0.01% 1266
2021
Q2 		$4.71M Buy
84,869
+54,145
+176% +$2.88M ﹤0.01% 2448
2021
Q1 		$1.44M Buy
30,724
+5,528
+22% +$268K ﹤0.01% 2910
2020
Q4 		$1.1M Buy
25,196
+3,329
+15% +$123K ﹤0.01% 2898
2020
Q3 		$800K Sell
21,867
-4,117
-16% -$140K ﹤0.01% 2912
2020
Q2 		$758K Buy
25,984
+1,018
+4% +$28.1K ﹤0.01% 2935
2020
Q1 		$653K Sell
24,966
-373,362
-94% -$11.4M ﹤0.01% 2944
2019
Q4 		$13.8M Buy
+398,328
New +$13.2M ﹤0.01% 1588

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's HCAT Position: Q1 2026 in Review

Invesco reduced its Health Catalyst (HCAT) stake by 0.39% in Q1 2026, selling an estimated $867 and leaving 118,130 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

Invesco first reported a position in HCAT in Q4 2019 and has held it in 26 quarters since. The position peaked at $31.7M in Q3 2021. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

  • Invesco held 118,130 shares of Health Catalyst worth $150K as of Q1 2026.
  • Invesco sold 461 Health Catalyst shares in Q1 2026, an estimated $867.
  • Health Catalyst made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3561 holding.
  • Invesco first reported a position in Health Catalyst in Q4 2019 and has held it in 26 quarters since.
  • Invesco's Health Catalyst position peaked at $31.7M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.